In-silico evaluation of Camellia sinensis phytochemicals for potential obesity and diabetes therapy
Abstract
Obesity is a chronic metabolic disease characterized by excessive body fat. Over 100 million adults in the US are considered obese, making it a significant metabolic disorder that is a risk factor for multiple metabolic diseases, including diabetes mellitus (DM), cardiovascular diseases, hypertension, dyslipidemia, renal and neurological dysfunctions, etc. There are a limited number of drugs available for the treatment of obesity. Lipase is one of the enzymes that plays a key role in lipid digestion and can be a target to treat weight gain and associated dyslipidemia and DM. However, there are continuous searches for new therapies, especially for traditional plant-based medicines due to the side effects associated with the currently available therapies. Metformin and statins are a couple of recent success stories of herbal and/or traditional medicine. Camellia sinensis (CS) is a species of evergreen shrub shown to have antioxidant and metabolic health benefits. Traditional medicine reports indicate its role in bodyweight loss. Since excess fat can lead to an increase in insulin resistance, lowering the excess fat by treating obesity can also slow the progression of DM. Our current study details an in-silico evaluation of phytochemicals of CS for lipase inhibitory activity to prevent fat absorption. Lipase is an enzyme that helps digest fat. By inhibiting lipase, the calories that would come from breaking down the fat will not be stored in the body and will also lead to…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.